Overview
Novasign provides software and consulting to speed bioprocess development. Its flagship Novasign Studio uses artificial intelligence and hybrid modeling to build digital twins that combine engineering knowledge with real process data to predict performance and product quality. This enables virtual experiments and outcome forecasting, reducing laboratory testing by 35–70% without needing programming expertise, and it also offers the Hybrid Modeling Toolbox as SaaS along with process modeling consulting and training. The platform is designed to be user-friendly for non-experts, and the company serves biopharmaceuticals, enzyme production, cultured foods, and academic research with a goal to shorten development timelines, cut costs, and improve process understanding, supported by partnerships and funding such as Repligen’s multi-million investment to scale internationally.
Work here?Claim your company
Simplify's take
What believers are saying
- Novasign posted 2026 webinars on regulator-traceable modeling and scale-up prediction, signaling active demand.
- Repligen's October 28, 2025 results cited Novasign as a strategic partnership priority.
- Novasign exhibited at BioProcess International 2026 and Repligen tech days across the U.S.
What critics are saying
- Repligen dependence exposes Novasign to partner-driven channel control and pricing pressure by 2027.
- Software validation inside GMP bioprocesses can stall deployments for years if models fail audits.
- A failed U.S. scale-up leaves Novasign trapped in Europe and vulnerable to commoditization.
What makes Novasign unique
- Novasign Studio unifies digital twins, hybrid modeling, and traceable workflows across bioprocess unit operations.
- Repligen integrated Novasign into TFF systems after the July 31, 2025 partnership.
- Its Vienna team packages software, consulting, and training for biopharma, enzymes, and cultured food.
Help us improve and share your feedback! Did you find this helpful?